New 31,000 square-foot facility will enhance Legend’s leading cell therapy portfolio and expand Legend’s R&D capabilities as a global cell...
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts Ongoing...
DATAcc is creating an open-source industry guide to address market challenges by bringing clarity on how and why to include...
GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics...
The First Digital Network for Research Flips the Script on Patient Recruitment PHILADELPHIA, Oct. 2, 2024 /PRNewswire/ -- Power, a...
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with...
DELRAY BEACH, Fla., Oct. 2, 2024 /PRNewswire/ -- The global life science analytics market is projected to grow from USD 35.69...
$34.9M ARPA-H project aims to disrupt therapies' market and radically improve treatment options HOUSTON, Oct. 2, 2024 /PRNewswire/ -- Rice...
Advancing CEPI's 100 Days Mission to Accelerate Vaccine Development DUSSELDORF, Germany, Oct. 2, 2024 /PRNewswire/ -- LenioBio, the leader in rapid...
UVA Cancer Center joins the extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision...
New Trial to Study Progerinin Treatment for Ultra-Rare ConditionBUSAN, KOREA; PEABODY, MA; and GERMANTOWN, MD / ACCESSWIRE / October 2,...
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet...
HUNTSVILLE, AL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its...
2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE)...
First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies...
100% 36-month overall survival (OS) and progression-free survival (PFS) rates in patients fully treated with Versamune® HPV combined with chemoradiation (N=8)88%...
INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognos Therapeutics, a private hi-tech medical technology company focused on the development...
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and...
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of...